The global demand for Next-Generation Sequencing Market, in terms of revenue, was worth of USD 10.77 billion in 2022 and is expected to reach USD 31.52 billion in 2029, growing at a CAGR of 16.58% from 2022 to 2029.
The global next-generation sequencing market is expected to grow at significant growth rate due to number of driving factor. Next generation sequencing technology (NGS) provides ideal throughput per data and genome studies can be performed quickly and cost-effective manner. NGS technologies are currently used for genome sequencing, investigation of genome diversity, metagenomics, epigenetics, discovery of non-coding RNAs, protein-binding sites and assessing gene-expression profiling. The development of next generation sequencing enables researchers to determine the microorganism’s behavior and understand the world of microorganisms from broader and deeper perspectives.
The COVID-19 pandemic has positively influenced the next generation sequencing market primarily due to the increase in COVID 19 patients across the globe. Public health service has become an essential part for controlling the spread of SARS-CoV-2. For example, the UK has been at the forefront of this response, with researchers collaborating with public health agencies and next generation sequencing trusts across the UK to form the COVID-19 Genomics. Several private businesses, institutes, and government bodies have enhanced their development in the NGS technology due to its advantageous aspects.
Higher initiative taken by government organization for clinical research, rapid adoption of genome technologies in biological sector and growing demand for cancer diagnostic procedures are responsible for the augmented market size of next generation sequencing. With the advancement of new sequencing technology, next-generation sequencing (NGS) has been applied increasingly in cancer genomics research over the past few years. NGS has been adopted in clinical oncology segment to advance personalized treatment of cancer. NGS is used to identify novel and rare cancer mutations, detect familial cancer mutation carriers, and offer molecular rationale for appropriate targeted therapy. For example, globally cancer is a leading cause of death, accounted for approximately 10 million deaths in 2020. It has observed that breast and lung cancer are most common cancer types recorded 2.26 and 2.21 million cases respectively in 2020. However, shortage of skill labors in operating sequencing technology may obstruct the growth of next generation sequencing market. In addition, next-generation sequencing technologies such as nanopore sequencing, are likely to become ubiquitous in diagnostic and healthcare settings will create a great opportunity for this market within the forecast period.
In response to growing advanced genome sequencing technology, manufacturers are significantly increasing physicians access to create rapid next generation results. Industry participants are also contributing to the growth of market by various developments and strategies. For example, Thermo Fisher Scientific has launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer which an automated, next-generation sequencing (NGS) platform that can offer effective results within les time. It is designed for use in clinical laboratories enables users to perform both diagnostic testing and clinical research on a single instrument. Additionally, on 13th January 2020, llumina partnered with Roche and software suite to grow adoption of genomics. Illumina is focused on three main areas to scale the reach and impact of genomics offering transition for genomics research. This can accelerate the clinical adoption of genomics and delivering fundamentally technology innovations. Besides above-mentioned facts, other players including BGI Group, Bio-Rad Laboratories, Eurofins GATC Biotech GmbH, and other are also promoting the NGS technologies and executing their plans to stay competitive.
North America has accounted for largest market share in the next generation sequencing market primarily due to the growing research & development activities in clinical areas, and presence of leading healthcare organizations. The growth of genetics and genomics science and applications in the U.S. has been gaining a huge traction in recent years, with research institutions innovating genome sequence technology to provide cost effective analysis of sequencing. Europe holds second leading position in the next generation sequencing market owing to the higher number of research centers and increased use of personalized medicine.
Analyst Comment, “Next generation sequencing technology has huge potential for clinical research area and companies in this industry will be focusing on automated next-generation sequencing (NGS) platform are all set to create a major transition for this market”.
NGS has revolutionized the biological sciences, allowing laboratories to perform a variety of applications and study biological systems at a level never before possible. Today's complex genomics questions demand a depth of information beyond the capabilities of traditional DNA sequencing technologies. NGS has filled that gap and has become an everyday tool to address these questions. The demand for NGS has increased tremendously in the recent past, due to which the following trending areas that are hosting the market and giving unique direction.
The pharmaceutical sector will benefit from the availability of technologically advanced NGS equipment that allows scientists and researchers to efficiently carry out the drug discovery process. The cost-effectiveness of NGS tools helps to greatly reduce the capital cost of research activities. For example, Illumina launched its latest high-output instrument, the NovaSeq, in 2107. The introduction of NovaSeq has enabled the sequencing of gigantic databases at a low expense.
The significant increase in research applications is mainly due to the high prevalence of rare genetic diseases which has encouraged the development of new gene therapies and treatments. Genome sequencing fully utilizes NGS consumables and equipment to help identify disease patterns. The various advantages of NGS tools will drive their high adoption for applications in the research process. According to the report, the next-generation sequencing industry size from research applications will account for nearly 6,282.24 revenue in 2028.
Exome sequencing is mainly used to identify specific protein-coding regions of genes that increase the clarity of the sequencing process. This method is highly preferred by doctors and researchers for analyzing genome sequences.
The contribution of pharmaceutical and biotechnology companies in the next-generation sequencing industry will experience 15.9% CAGR by 2028. These companies are focusing on extensive R&D activities to develop effective drugs to treat several genetic and chronic conditions. The adoption of technologically advanced NGS tools allows these companies to produce commercially viable and reliable drugs.
There are ideal conditions for the expansion of the next-generation sequencing business in 2018. Extensive government funding and support have fueled the high adoption of NGS tools in the research process. Favorable regulatory norms and trade policies will boost industry growth during the forecast period.
The development of next-generation sequencing technologies has revolutionized data interpretation, gene mapping, and analysis of large genome sequences that help scientists and researchers develop drugs for various diseases. For example, the use of NGS technology in pathogen detection is considered an alternative method for characterizing unwanted pathogens in medical samples. Increasing the use of NGS tools in various clinical settings and drug development will drive industry expansion.
Solexa Company has invented a new approach to sequencing. Solexa was acquired by Illumina, which began commercializing the Illumina/Solexa Genome Analyzer (GA). Illumina technology is sequencing by synthesis and is currently the most widely used technology in the NGS market. It currently offers sequencing systems such as MiSeq, HiSeq 2500, HiSeq 3000, HiSeq 4000, HiSeq X Ten, HiSeq X Five, NextSeq 550.
NGS has very wide applications, it can be used for whole-genome sequencing, targeted region sequencing, transcriptome analysis, metagenomics, small RNA detection, methylation profiling, and genome-wide protein-nucleic acid interaction analysis, helping people unlock the power of the gene.
The Roche/454 sequencer appeared on the market in 2005, using a pyrosequencing technique that is based on the detection of a pyrophosphate containing each nucleotide in a new synthetic DNA strand. The pyrosequencing technique is a sequential bi-synthesis approach.
DNA samples are randomly fragmented, and each fragment is primers attached to the surface of the beads containing oligonucleotides complementary to the DNA fragments so that each bead corresponds to a single fragment. Furthermore, Roche/454 has launched an updated instrument called GS FLX+ that generates reads up to 1000 bp in length and can produce 1 million reads per run. Other features of Roche/454 devices are listed. Roche/454 is capable of generating relatively long reads that are easy to map to the reference genome.
Supported Oligonucleotide Ligation and Detection (SOLiD) is an NGS sequencer marketed by Life Technologies. In 2007, Applied Biosystems (ABI) acquired SOLiD and developed the ABI/SOLID sequencing technology that adopts the binding (SBL) approach.
ABI/SOLiD launched the first sequencer that produced short reads with a length of 35 bp and an output of 3 Gb/run and continued to improve their sequencing to increase the length of reads to 75 bp with an output of up to 30 Gb/run. The strength of the ABI/SOLiD platform is the high accuracy because each base is read twice, while the drawback is the relatively short read time and long duration.
In 2010, Life Technologies commercialized its ion torrent semiconductor sequencing technology. It is similar to 454 pyrosequencing technology, but it does not use fluorescently labeled nucleotides like other second-generation technologies. It is based on the detection of hydrogen ions released during the sequencing process.
In particular, the ion torrent uses a chip that contains a set of microscopic wells, each containing a bead of many identical particles. With each nucleotide incorporated into the bead, a hydrogen ion is released, which changes the pH of the solution. This change is detected by a sensor attached to the bottom of the microwell and converted into a voltage signal that is proportional to the number of nucleotides incorporated.
Pacific Biosciences developed the first genomic sequencer using the SMRT approach, and it is the most widely used third-generation sequencing technology. PacBio SMRT sequencing can be used to obtain high-quality genome sequences for genomic de novo sequencing, obtain complete transcriptome information and detect alternative splicing isoforms, diverse mutations, and epigenetic modifications in target regions, and more.
Oxford Nanopore Sequencing (ONT) was developed as a technique to determine the sequence of nucleotides in a DNA sequence. In 2014, Oxford Nanopore Technologies released the MinION device that promises to generate long reads that ensure a better resolution structural genomic type and material repeatability. It is a mobile single molecule nanopore sequencing device that measures four inches in length and is connected to a laptop computer's USB 3.0 port. The device has been released for testing by the user community as part of the MinION Access Program (MAP) to test the functionality of the MinION sequencer.
Nanopore sequencing is a remarkable, scalable technology that enables direct, real-time analysis of long RNA or DNA fragments. It works by monitoring changes in electrical current as nucleic acids pass through protein nanopores. The resulting signal is decoded to provide a detailed DNA or RNA sequence.
Next generation sequencing has undergone significant technological improvements over the past few years. Also, based on this technology, a large number of technological improvements are expected in the coming period.
A major advance in NGS technology occurred with the development of paired-end (PE) sequencing. PE sequencing involves sequencing both the DNA fragments & soft end of the library and aligning forward further reverse reads to read pairs. Analysis of differential read pair spacing also allows the removal of PCR duplicates, a common artifact from PCR amplification during library preparation. Furthermore, PE sequencing produces a large number of SNV calls after read-pair alignment. While some methods are best served by single-read sequencings, such as small RNA sequencing, most researchers currently use the paired-end approach.
The digital nature of NGS allows virtually unlimited dynamic range for read-count methods, such as gene expression analysis. Microarrays measure the continuous signal intensity and detection range is limited by noise at the low end and signal saturation at the high end, whereas NGS measures discrete, digital sequence read counts. By increasing or decreasing the number of sequences reads, practitioners can tune the sensitivity of the experiment to accommodate different study objectives. Because the dynamic range with NGS is adjustable and nearly unlimited, researchers can quantify subtle gene expression changes with greater sensitivity than traditional microarray-based methods. A scanning run scan is designed to zoom in on specific regions of the genome with higher resolution or to provide a more detailed view with lower resolution.
The capability to effortlessly tune the level of coverage offers several experimental design advantages. For example, somatic mutations may only exist in a small proportion of cells in a given tissue sample. Using mixed tumor-normal cell samples, the region of DNA harboring the mutation must be sequenced at very high coverage, often wards of 1000×, to detect low-frequency mutations in mixed cell populations. At the other end of the coverage spectrum, methods such as genome wide variant detection usually require very low coverage levels. In this case, the study design involves sequencing many samples (hundreds to thousands) at low resolution, to achieve greater statistical power in a given population.
With Illumina NGS, library preparation has rapidly improved. The first NGS library prep protocols involved multiple steps of random fragmentation of a DNA or RNA sample, gel-based size selection, ligation of platform-specific oligonucleotides, PCR amplification, and purification. The 1-2 days required to prepare these initial NGS libraries was a great improvement over traditional cloning techniques, but current NGS protocols, such as Nextera® XTDNA Library Preparation, have reduced library preparation times to less than 90 minutes. 10 Gel-free kits are also available for PCR-free and sensitive sequencing methods. PCR-free library preparation kits result in superior coverage of traditionally challenging genes such as highly AT/GC-rich regions, promoters, and homopolymeric regions.
Along with the increase in data output per run, sample throughput per run in NGS has also increased over time. Multiplexing allows a large number of libraries to be combined in a single sequence and sequenced simultaneously. With multiplex libraries, unique sequences are added to each DNA fragment during library preparation so that each read can be identified and sequenced prior to final data analysis. Together with PE sequencing and multiplexing, NGS has dramatically reduced the time required for data for multi-sample studies and enabled researchers to move data quickly and easily from the experiment to the experiment.
While the latest NGS platforms can produce large amounts of data output, NGS technology is also highly flexible and scalable. Sequencing systems are available for every method and scale of the study, from small laboratories to large genome centers. Illumina NGS instruments range from the benchtop MiniSeq™ System, with outputs ranging from 1.8-7.5 Gb for targeted sequencing studies, to the NovaSeq 6000 System, which can generate an impressive 6 Tb and 20 Breadsin~ 2 days of study per population.
Flexible run configurations are also built into the design of Illumina NGS sequencers. For example, the HiSeq® 2500 system offers two run modes and single ordinal flow cell sequencing while the NextSeq® series of sequencing systems offer two flow cell types to accommodate different throughput requirements. The HiSeq 3000/4000S series uses the same patterned flow cell technology as the HiSeq X instruments for cost-effective production-scale sequencing. The new NovaSeq series of systems feature the latest high-performance imaging with the next generation of Illumina Pattern's flow cell technology to provide a massive increase in throughput. This flexibility allows researchers to configure runs with the instrument of their choice to suit their specific study requirements.
All technologies as well as new trendy sequencing methods are being widely used. These are rocketing the market sales for next generation sequencing.
|Historical data||2016 - 2021|
|Forecast Period||2022 - 2029|
|Market Size in 2022:||USD 10.77 Billion|
|Base year considered||2021|
|Forecast Period CAGR %:||
|Market Size Expected in 2029:||USD 31.52 Billion|
|Tables, Charts & Figures:||175|
|Next-Generation Sequencing Company||Thermo Fisher Scientific, Illumina, PerkinElmer, BGI Group, Agilent Technologies, QIAGEN, Genomatrix GmbH, Oxford Nanopore Technologies, Hoffman-La Roche Ltd., Bio-Rad Laboratories, Eurofins GATC Biotech GmbH, DNASTAR lnc, Roche, Pacific Biosciences, others.|
|Segments Covered||By Type of Sequencing, By Product Type, By Technology, By Application, By End-User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|